Connective Tissue Diseases: Clinical Trials

1,049 trials for Connective Tissue Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

664 completed, 100 terminated, 90 unknown, 75 recruiting. 1049 Phase 3, 145 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 31049Completed 664, Terminated 100, Unknown 90, Recruiting 75, Active not recruiting 60, Withdrawn 25, Not yet recruiting 21, Enrolling by invitation 13, Suspended 1
Phase 2145Completed 72, Unknown 30, Terminated 13, Recruiting 12, Active not recruiting 8, Not yet recruiting 5, Withdrawn 3, Enrolling by invitation 2

Follow Connective Tissue Diseases: new trials by email Literature Review of Connective Tissue Diseases trials Research Report on Connective Tissue Diseases

Trials (filtered) newest first · largest first

All 1,049 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERIT
Trametinib - HCM, Noonan Syndrome and Other Rasopathy
Phase 3Not yet recruitingCarelon Research252027-08-012026-09-14
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
BMS-986353, Fludarabine, Cyclophosphamide - Systemic Sclerosis
Phase 3Not yet recruitingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company922027-02-032026-09-18
A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)
garetosmab - Fibrodysplasia Ossificans Progressiva, FOP
Phase 3Not yet recruitingRegeneron Pharmaceuticals182027-02-022026-11-12
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease
Phase 3Not yet recruitingBristol-Myers Squibb23002026-12-312026-09-03
A Pilot Multicentric Open Study Assessing the Efficacy and Safety of NEMOlizumab in Patients ≥ 12yo With Dystrophic Epidermolysis Bullosa
Neolizumab - Dystrophic Epidermolysis Bullosa
Phase 2 / Phase 3Not yet recruitingCentre Hospitalier Universitaire de Nice152026-12-312026-11-09
A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further.
ABBV-722, Upadacitinib, Placebo for ABBV-722 - Systemic Sclerosis
Phase 2 / Phase 3Not yet recruitingAbbVie5802026-12-112026-11-12
ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months.
Hydroxychloroquine (HCQ), No Hydroxychloroquine (HCQ), Prednisone or Prednisolone - Rheumatic Fever, Rheumatic Heart Disease in Children
Phase 3Not yet recruitingStarship Child Health, Te Toka Tumai Auckland6002026-12-012026-10-07
Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)
Tralesinidase alfa (TA) - MPS IIIB
Phase 3Not yet recruitingSpruce Biosciences142026-12-012026-09-21
Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus
Afimetoran, Placebo - Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus
Phase 2 / Phase 3RecruitingBeeline Medicines Corporation3902026-11-032026-11-10
DEPART Study at Yale
Radiation Therapy - Dupuytren's Contracture
Phase 3Not yet recruitingYale University1582026-11-012026-10-13
Naproxen Versus Placebo as Adjunct Treatment of Cellulitis
enteric-coated naproxen, Cephalexin Tablets, Placebo - Cellulitis, Skin Disease, Infectious
Phase 3Not yet recruitingOttawa Hospital Research Institute8842026-11-012026-10-20
A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]
Enpatoran - Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
Phase 3RecruitingEMD Serono Research & Development Institute, Inc.4042026-10-222026-11-10
the Effect of Ginkgo Biloba on Rheumatoid Arthritis Patients
Ginkgo Biloba Extract (120 mg ) manufuctured by EMA PHARM - Rheumatoid Arthritis (RA), Manegmentof Rheumatoid Arthritis
Phase 2 / Phase 3Not yet recruitingAin Shams University502026-10-152026-10-06
The Ultrasound-Guided Dextrose Prolotherapy in Ehlers-Danlos Syndrome Patients
Dextrose 50% Intravenous Solution, Lidocaine 1% Injectable Solution - Ehlers-Danlos Syndrome, Low Back Pain
Phase 3WithdrawnTulane University2026-10-052026-10-08
A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
obinutuzumab (RO5072759) - Lupus Nephritis
Phase 3Not yet recruitingZhao Minghui702026-09-102026-08-26
The Effect of Nicorandil on Rheumatoid Arthritis Patients
Nicorandil Oral Tablet, Placebo, conventional synthetic antirheumatic drugs (cDMARDs) - Rheumatoid Arthritis (RA)
Phase 2 / Phase 3RecruitingAin Shams University702026-09-062026-09-16
Nicorandil in Atherosclerosis Risk in Patients With Rheumatoid Arthritis
Nicorandil 10 MG Oral scored Tablet, DMARD maintenance - Rheumatoid Arthritis (RA, Atherosclerosis
Phase 3Not yet recruitingTanta University462026-09-012026-09-11
A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus
Anifrolumab - Lupus Erythematosus, Systemic
Phase 3RecruitingAstraZeneca4172026-08-312026-10-22
Perioperative Haemostasis, Procedure-Related Pain After Physiological or Pharmacological Modifications of Local Anaesthesia Around the Eyes
Sodium Bicarbonate (NaHCO3), Warmed lignocaine, Hyaluronidase Injection - Dermatochalasis of Upper Eyelid, Blepharoplasty
Phase 3Not yet recruitingPrince of Wales Hospital, Shatin, Hong Kong802026-08-012026-08-03
Efficacy of A Non-Invasive Botulinum Toxin Microneedle Pad for the Treatment of Secondary Raynaud's Phenomenon
Botulinum toxin A via microneedle, Control (Normal saline) - Systemic Sclerosis (SSc), Raynaud Disease Secondary to Scleroderma
Phase 3Not yet recruitingKhon Kaen University722026-08-012026-08-17

Showing 20 of 1049. Sign in to see all of them.

Narrower conditions

Arthritis, Rheumatoid (451)  ·  Lupus Erythematosus, Systemic (119)  ·  Arthritis, Juvenile (79)  ·  Arthritis (57)  ·  Lupus Nephritis (52)  ·  Scleroderma, Systemic (50)  ·  Scleroderma, Diffuse (43)  ·  Cellulitis (37)  ·  Autoimmune Diseases (36)  ·  Dermatomyositis (30)  ·  Osteoarthritis (28)  ·  Sjogren's Syndrome (26)  ·  Polymyalgia Rheumatica (20)  ·  Rheumatic Diseases (20)

Broader conditions

Skin and Connective Tissue Diseases (1048)  ·  Immune System Diseases (702)  ·  Autoimmune Diseases (680)  ·  Musculoskeletal Diseases (665)  ·  Rheumatic Diseases (571)  ·  Joint Diseases (559)  ·  Arthritis (517)  ·  Skin Diseases (157)  ·  Pathological Conditions, Signs and Symptoms (143)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (113)  ·  Pathologic Processes (108)  ·  Genetic Diseases, Inborn (91)  ·  Urogenital Diseases (77)  ·  Muscular Diseases (73)

Interventions

Methotrexate (115)  ·  tocilizumab (94)  ·  Adalimumab (51)  ·  Rituximab (46)  ·  Abatacept (37)  ·  Etanercept (35)  ·  Certolizumab Pegol (31)  ·  Infliximab (29)  ·  Mycophenolic Acid (23)  ·  Cyclophosphamide (20)  ·  baricitinib (19)  ·  tofacitinib (19)  ·  Prednisone (18)  ·  belimumab (17)  ·  golimumab (16)

Sponsors

Hoffmann-La Roche (81)  ·  Bristol-Myers Squibb (32)  ·  Novartis Pharmaceuticals (30)  ·  Amgen (29)  ·  Pfizer (27)  ·  Eli Lilly and Company (22)  ·  UCB Pharma (20)  ·  Abbott (18)  ·  GlaxoSmithKline (17)  ·  AstraZeneca (16)  ·  Genentech, Inc. (15)  ·  AbbVie (13)  ·  Janssen Research & Development, LLC (13)  ·  Sanofi (13)  ·  Assistance Publique - Hôpitaux de Paris (12)

Countries

United States (465)  ·  Germany (271)  ·  Spain (235)  ·  France (233)  ·  Poland (220)  ·  Canada (215)  ·  United Kingdom (205)  ·  Italy (197)  ·  Mexico (193)  ·  Argentina (175)  ·  Brazil (167)  ·  Japan (162)  ·  South Korea (162)  ·  Australia (156)  ·  Hungary (155)

Top investigators

Takahiro Kakehi (8)

Results publications

PMID 27338778, PMID 33687069, PMID 29244149, PMID 30649524, PMID 33263165, PMID 36526796, PMID 36600185, PMID 36601090, PMID 36931693, PMID 28143815, PMID 32816215, PMID 33127856, PMID 34870800, PMID 37453736, PMID 25047021, PMID 33874971, PMID 30177460, PMID 34041702, PMID 34706874, PMID 35577477, PMID 36715850, PMID 36754548, PMID 36814062, PMID 37308218, PMID 37945286, PMID 37982966, PMID 38958913, PMID 39192350, PMID 40875187, PMID 22491018, PMID 26275429, PMID 29463520, PMID 29949132, PMID 30219772, PMID 31610021, PMID 33059710, PMID 33115760, PMID 34921355, PMID 36125701, PMID 37925660, PMID 41448717, PMID 24429164, PMID 24498318, PMID 27889300, PMID 29246162, PMID 30054164, PMID 30058112, PMID 32414425, PMID 33057725, PMID 34519964

NIH funding

2023 (36), 2009 (17), 2015 (17), 2016 (11), 2008 (10), 2019 (10), 2014 (9), 2017 (9), 2018 (9), 2025 (7), 2005 (6), 2004 (4), U01AR042540 (2), N01AR022265 (1), P60AR047784 (1)